Pancreatic Resectability in Cancers with Known Limited Extension (PRICKLE) – a single-arm phase 2a study of gemcitabine (Gem) plus Nab-paclitaxel (NabP) for borderline (un)resectable pancreatic ductal adenocarcinoma (BrPDAC)